Management of cutaneous T-cell lymphomas: Established and emergent therapies

被引：1
作者：
Wain, Thevaki [1 ]
Venning, Victoria L. [2 ,3 ]
Consuegra, Germana [1 ,3 ]
Fernandez-Penas, Pablo [1 ,2 ,3 ]
Wells, Jillian [1 ,3 ]
机构：
[1] Westmead Hosp, Dept Dermatol, Westmead, NSW, Australia
[2] Skin Hosp, 7 Ashley Lane, Westmead, NSW, Australia
[3] Univ Sydney, Fac Med, Sydney, NSW, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2019年 / 60卷 / 03期
关键词：
cutaneous lymphoproliferative disorders; cutaneous T-cell lymphoma; management; mycosis fungoides; Sezary syndrome; ELECTRON-BEAM THERAPY; ADVANCED MYCOSIS-FUNGOIDES; LOW-DOSE METHOTREXATE; MULTICENTER PHASE-II; SEZARY-SYNDROME; CLINICAL-TRIAL; STAGE; CHEMOTHERAPY; DISEASE; INTERFERON;
D O I：
10.1111/ajd.13011
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Cutaneous T-cell lymphoma is an uncommon group of non-Hodgkin's lymphoma primarily affecting the skin. It is comprised of a variety of entities with different clinical behaviours and prognosis. Mycosis fungoides is the commonest subtype, and Sezary syndrome is a much rarer form of cutaneous T-cell lymphoma. At this stage, control rather than cure is the goal of therapy, with particular emphasis placed on preserving quality of life. Our review of the efficacy, safety profile and accessibility of treatment modalities for mycosis fungoides/Sezary syndrome is a tailored guide for the clinician treating these rare conditions.
引用
收藏
页码：200 / 208
页数：9
相关论文
共 53 条
  • [1] Akpek G, 1999, CANCER-AM CANCER SOC, V86, P1368, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO
  • [2] 2-8
  • [3] Alberti-Violetti Silvia, 2015, Clin Lymphoma Myeloma Leuk, V15, pe105, DOI 10.1016/j.clml.2015.02.027
  • [4] [Anonymous], 2014, J AM ACAD DERMATOL
  • [5] Tazarotene 0.1% gel for refractory mycosis fungoides lesions: An open-label pilot study
    Apisarnthanarax, N
    Talpur, R
    Ward, S
    Ni, X
    Kim, HW
    Duvic, M
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (04) : 600 - 607
  • [6] Extracorporeal photopheresis for the treatment of Sezary syndrome using a novel treatment protocol
    Arulogun, Suzanne
    Prince, H. Miles
    Gambell, Peter
    Lade, Stephen
    Ryan, Gail
    Eaton, Eve
    McCormack, Christopher
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 59 (04) : 589 - 595
  • [7] Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sezary syndrome
    Aviles, Agustin
    Nambo, Jesus
    Neri, Natividad
    Castaneda, Claudia
    Cleto, Sergio
    Gonzalez, Martha
    Huerta-Guzman, Judith
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (06) : 836 - 840
  • [8] Treatment of cutaneous T-cell lymphoma with alitretinoin gel
    Bassiri-Tehrani, S
    Cohen, DE
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2002, 41 (02) : 104 - 106
  • [9] Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma
    Breneman, D
    Duvic, M
    Kuzel, T
    Yocum, R
    Truglia, J
    Stevens, VJ
    [J]. ARCHIVES OF DERMATOLOGY, 2002, 138 (03) : 325 - 332
  • [10] Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas
    de Masson, A.
    Guitera, P.
    Brice, P.
    Moulonguet, I.
    Mouly, F.
    Bouaziz, J. -D.
    Battistella, M.
    Madelaine, I.
    Roux, J.
    Ram-Wolff, C.
    Cayuela, J. -M.
    Bachelez, H.
    Bensussan, A.
    Michel, L.
    Bagot, M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (03) : 720 - 724
123456